Phase
Condition
Leukemia
Treatment
Revumenib
Cytarabine
Venetoclax
Clinical Study ID
Ages 1-30 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria: Participants must have a diagnosis of AML or ALAL and meet the criteria below:
Refractory leukemia, defined as persistent leukemia after at least two courses ofinduction chemotherapy, or relapsed leukemia, defined as the re-appearance ofleukemia after the achievement of remission. Patients must have ≥5% blasts in thebone marrow as assessed by morphology or ≥1% blasts flow cytometry. However, if anadequate bone marrow sample cannot be obtained (e.g., in a patient with acutemegakaryoblastic leukemia with marrow fibrosis), patients may be enrolled if thereis unequivocal evidence of leukemia with ≥5% blasts by morphology or ≥1% blasts flowcytometry in the blood.
Presence of KMT2A rearrangement (KMT2Ar), NUP98 rearrangement (NUP98r), NPM1mutation or fusion, PICALM::MLLT10, DEK::NUP214, UBTF-TD, KAT6A::CREBBP, orSET::NUP214
Adequate organ function, defined as total bilirubin < 1.5 × institutional upperlimit of normal for age or normal conjugated bilirubin (for patients with knownGilbert's syndrome, total bilirubin <3 × the ULN) unless attributed to leukemia,calculated creatinine clearance ≥60 mL/min/1.73 m^2, and left ventricular ejectionfraction ≥ 40%
QTcF < 480 msec (average of triplicate)
Age ≥ 1 year and ≤ 30 years. The upper age limit may be defined by each institution,but may not exceed 30 years.
Lansky ≥ 60 for patients who are < 16 years old and Karnofsky ≥ 60% for patients whoare > 16 years old.
At least 14 days or 5 half-lives (whichever is longer) must have elapsed since thecompletion of myelosuppressive therapy, with the exception of low-dose therapy usedfor cytoreduction according to institutional standards, such as hydroxyurea orlow-dose cytarabine (up to 200 mg/m^2/day). In addition, all toxicities must haveresolved to grade 1 or less.
Patients must have a leukocyte count <25,000 cells/uL. Low-dose therapy, such ashydroxyurea or cytarabine as described above, to achieve this limit is acceptable.
For patients who have received prior HCT, there can be no evidence of GVHD andgreater than 60 days must have elapsed since the HCT, and patients should be offcalcineurin inhibitors for at least 28 days prior to the start of protocol therapy.Physiologic prednisone for the treatment of adrenal insufficiency is acceptable..
Patients must be taking posaconazole or voriconazole, which must be started at least 24 hours prior to the start of therapy.
Patients of reproductive potential must agree to use effective contraception for theduration of study participation.
Patients must be able to swallow tablets.
Patients who meet the criteria listed above are eligible for enrollment and treatment on the trial. However, patients in first relapse who are suitable for and willing to receive intensive remission induction therapy should be offered such therapy if deemed appropriate by the treating physician.
Exclusion
Exclusion Criteria:
Patients who are pregnant or breastfeeding are not eligible.
Patients with Down syndrome, acute promyelocytic leukemia, juvenile myelomonocyticleukemia, or bone marrow failure syndromes are not eligible.
Patients with uncontrolled infection are not eligible. Patients with infections thatare controlled on concurrent anti-microbial agents are eligible.
Study Design
Study Description
Connect with a study center
Children's Mercy Hospital of Kansas City
Kansas City, Missouri 64108
United StatesActive - Recruiting
Memorial Sloan- Kettering Cancer Center
New York, New York 10065
United StatesActive - Recruiting
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio 45229
United StatesActive - Recruiting
St. Jude Children's Research Hospital
Memphis, Tennessee 38105
United StatesActive - Recruiting
UT Southwestern/Simmons Cancer Center
Dallas, Texas 75390
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.